Vimarsana
Biggest News Aggregation in the World

Page 3 - Nasdaq Cccc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Cccc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cccc Today - Breaking & Trending Today

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has been given a consensus recommendation of “Hold” by the seven research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and two have issued a buy recommendation on the […]

C4 Therapeutics Announces Chief Financial Officer - Vimarsana News

C4 Therapeutics Announces Chief Financial Officer

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...

Examining the Volatility of C4 Therapeutics Inc.'s (CCCC) Stock - Vimarsana News

Examining the Volatility of C4 Therapeutics Inc.'s (CCCC) Stock

The stock of C4 Therapeutics Inc. (CCCC) has seen a -11.48% decrease in the past week, with a -21.02% drop in the past month, and a -13.57% decrease in the past quarter. The volatility ratio for the week is 4.37%, and the volatility levels for the past 30 days are at 4.53% for CCCC. The simple movin

C4 Therapeutics (NASDAQ:CCCC) Price Target Cut to $20.00 - Vimarsana News

C4 Therapeutics (NASDAQ:CCCC) Price Target Cut to $20.00

C4 Therapeutics (NASDAQ:CCCC – Free Report) had its price objective decreased by UBS Group from $22.00 to $20.00 in a research note published on Friday, FlyOnTheWall reports. Several other analysts have also commented on the stock. Evercore ISI lowered their price objective on shares of C4 Therapeutics to $10.00 in a report on Tuesday, May […]

C4 Therapeutics (NASDAQ:CCCC) Given New $20.00 Price Target at UBS Group - Vimarsana News

C4 Therapeutics (NASDAQ:CCCC) Given New $20.00 Price Target at UBS Group

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) had its price objective decreased by UBS Group from $22.00 to $20.00 in a report issued on Friday, FlyOnTheWall reports. UBS Group’s price target would indicate a potential upside of 468.18% from the stock’s current price. Several other equities research analysts have also issued reports on the company. […]